In this Sunday morning session, Dr. Richard Barr, PhD, and colleagues will present results from a study they conducted using data from the American College of Radiology Imaging Network (ACRIN) 6666 trial to ascertain the frequency and malignancy rate of BI-RADS 3 ultrasound lesions.
Out of 2,662 trial participants, 519 (19.5%) had 745 BI-RADS 3 lesions, the team found. Of these lesions, 124 (16.6%) were biopsied; six of these biopsied lesions were malignant (representing 4.8% of biopsies and 0.8% of BI-RADS 3 lesions). The six malignant lesions occurred in five (1%) of the 519 participants, and five of the six malignancies were invasive.
What's the bottom line? BI-RADS 3 lesions are common on screening ultrasound, but fewer than 2% are malignant, according to Barr's group.